Category: Clinical Trials

Pfizer has reported positive outcomes from a Phase IIb clinical trial evaluating berobenatide, an investigational peptide therapeutic. The announcement adds to a growing body of evidence supporting the potential of peptide-based approaches in modern medicine, and represents a meaningful milestone as the compound progresses through the clinical development pipeline.

Phase IIb trials are a critical checkpoint in drug development, designed to further establish efficacy and safety in a larger patient population after initial proof-of-concept studies. Achieving positive results at this stage suggests that berobenatide is demonstrating the kind of consistent performance that can support advancement into larger, late-stage Phase III trials — often the final step before regulatory review.

Peptide therapeutics like berobenatide continue to attract significant interest from major pharmaceutical companies because of their ability to combine the precision of biologic drugs with the manufacturing advantages of smaller molecules. This class of treatment has already produced several notable success stories in recent years, and continued positive trial data from a company with Pfizer’s scale and resources underscores the ongoing momentum behind peptide-based drug development.

While specific details about the mechanism, target condition, and full data set from this trial were not extensively detailed in the initial announcement, the fact that the study met its goals is an encouraging signal for patients and the broader research community. Successful mid-stage trials help pave the way for expanded studies, additional regulatory engagement, and eventually, if all goes well, new treatment options reaching the people who need them.

True North Labs will continue to monitor developments related to berobenatide as more information becomes available, including any future trial designs, patient populations, and regulatory milestones. As always, we’re glad to see continued investment and positive momentum in peptide science.

This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment or therapy.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Pfizer reports positive results from Phase IIb trial of berobenatide – Clinical Trials Arena

Arch Biopartners has announced plans to expand its ongoing clinical trial for LSALT peptide into the United States, marking a significant step forward for the company’s drug development program. LSALT peptide is an investigational therapy that has been under study for its potential to help protect organs during periods of acute stress, such as major surgery or critical illness.

Expanding a clinical trial into a new country, particularly one with a large and diverse patient population like the US, is often viewed as a positive sign of progress. It typically indicates that earlier trial phases have generated encouraging enough data to justify broader investment and regulatory engagement. A larger, more geographically diverse trial can also help researchers gather more robust evidence about how a treatment performs across different patient populations, which is valuable for eventual regulatory review.

For patients and clinicians, the expansion of trial sites means more opportunities for eligible individuals to participate in cutting-edge research and potentially access an investigational therapy before it becomes widely available. It also reflects the broader momentum in the peptide therapeutics space, where companies are increasingly exploring how short protein fragments can be harnessed to address complex medical challenges, including organ protection and inflammation management.

Arch Biopartners’ move to grow its US footprint suggests confidence in the LSALT peptide program and a commitment to advancing the science through rigorous clinical evaluation. As with all early and mid-stage drug development programs, continued trial expansion and data collection will be important steps on the path toward understanding the full potential of this therapy.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Arch Biopartners plans US expansion of LSALT peptide trial – Clinical Trials Arena

Researchers at the National Institutes of Health have launched a new clinical trial investigating an innovative combination approach for people with early-stage, operable non-small cell lung cancer (NSCLC). The study, known as AZA-AEGEAN, pairs an inhaled form of the epigenetic drug azacytidine with the already-approved neoadjuvant regimen of durvalumab and platinum-based chemotherapy, exploring whether this combined epigenetic-immunotherapy strategy can further improve outcomes before surgery.

NSCLC remains the most common form of lung cancer, and while surgery is the standard treatment for early-stage disease, tumors can sometimes return even after successful removal. Durvalumab plus chemotherapy given before surgery is already an FDA-approved option shown to help some patients, but researchers are now asking whether adding inhaled azacytidine could offer an additional benefit by targeting cancer cells directly in the lungs.

What makes this approach particularly promising is the delivery method: rather than delivering azacytidine intravenously, as it is used in other approved indications, the trial uses a nebulized, inhaled version similar to an asthma inhaler mist. This route is designed to concentrate the drug’s effects directly in lung tissue while limiting how much enters the bloodstream, potentially reducing systemic exposure while still working to sensitize tumor cells epigenetically before the immune-boosting and chemotherapy components take effect.

The trial is carefully structured to gather robust data, including pre- and post-treatment biopsies, imaging, and bronchial fluid collection, allowing researchers to closely study how the combination affects tumor tissue at a cellular level. Participants will undergo three treatment cycles before their planned surgery, followed by regular monitoring for up to three years afterward, an approach that should provide valuable long-term insight into how this regimen influences recurrence and recovery.

This type of research represents an encouraging step in the ongoing effort to refine and personalize treatment for early-stage lung cancer, potentially opening the door to more effective pre-surgical options that combine multiple therapeutic strategies. While it is still early days for this specific combination, trials like this help build the foundation for future advances in thoracic oncology care. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) – a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

A new clinical trial, known as MK-2870-036 (also called TroFuse-036, GOG-3123, and ENGOT-cx22), is now underway to explore innovative treatment options for people living with metastatic cervical cancer. The study focuses on a promising combination approach: pairing an antibody-drug conjugate called sacituzumab tirumotecan (sac-TMT, also known as MK-2870) with the immunotherapy drug pembrolizumab, and in some cases, the targeted therapy bevacizumab.

Antibody-drug conjugates represent an exciting frontier in cancer treatment because they are designed to precisely target cancer cells while sparing healthy tissue. Sac-TMT works by attaching to specific markers found on cancer cells and delivering its therapeutic payload directly to those cells, potentially offering a more focused approach compared to traditional chemotherapy.

This trial is particularly encouraging because it is being conducted as a first-line maintenance treatment study, meaning researchers are looking at how this combination might help patients continue to do well after their initial cancer treatment. The study will compare outcomes between patients receiving the new combination therapy and those receiving standard treatment, with a focus on both safety and how well patients tolerate the combined medicines.

Key goals of the research include understanding whether this combination approach helps people live longer overall, and whether it can delay cancer progression compared to current standard treatments. The inclusion of bevacizumab as an optional component in some treatment arms also allows researchers to explore multiple therapeutic strategies within a single, well-designed study framework.

This type of collaborative, multi-institutional research effort—spanning multiple international study groups including GOG and ENGOT—reflects the ongoing commitment of the oncology research community to find better treatment options for patients facing metastatic cervical cancer. Trials like this one are essential steps in the process of bringing new, potentially more effective therapies to patients who need them.

This article is for informational purposes only and is not intended as medical advice. Individuals interested in clinical trials should consult with their healthcare provider.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

A newly registered Phase 2 clinical trial is set to explore the safety and effectiveness of VS-7375, an investigational therapy designed to target tumors driven by the KRAS G12D mutation, in patients with metastatic pancreatic cancer. The study will examine VS-7375 both as a standalone treatment and in combination with cetuximab, an established therapy already used in several cancer treatment regimens.

Pancreatic cancer remains one of the most challenging cancers to treat, and mutations in the KRAS gene—particularly the G12D variant—are among the most common genetic drivers of the disease. For years, KRAS mutations were considered extremely difficult to target with precision therapies, so the continued development of drugs like VS-7375 represents meaningful progress in the effort to bring targeted treatment options to patients who currently have limited choices.

By testing VS-7375 both alone and alongside cetuximab, researchers aim to learn whether combining approaches could enhance treatment response compared to single-agent therapy. This kind of combination strategy is common in oncology research, as it allows scientists to explore whether pairing therapies with different mechanisms of action can improve outcomes for patients with aggressive, hard-to-treat tumors.

The advancement of this trial into Phase 2 signals that earlier research supported enough safety and preliminary activity to justify further investigation in a larger patient population. While much work remains before any conclusions can be drawn about long-term efficacy, the initiation of this study reflects the broader momentum in precision medicine—where treatments are increasingly designed to match the specific genetic profile of a patient’s tumor rather than relying on one-size-fits-all approaches.

For patients and families affected by KRAS G12D-mutated pancreatic cancer, the launch of new targeted studies like this one offers a hopeful sign that research in this area continues to move forward. As with all investigational treatments, results from this trial will need to be thoroughly reviewed before any conclusions can be made about its safety or effectiveness. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

A promising new clinical trial is investigating whether a peptide-based cancer vaccine can enhance the effectiveness of immunotherapy in patients battling advanced colorectal cancer. The multicenter, open-label phase II study is testing the combination of PolyPEPI1018, an experimental peptide vaccine, with atezolizumab, an established immunotherapy drug, in patients with microsatellite stable (MSS) colorectal cancer who have already progressed through two or three prior treatment regimens.

This patient population represents one of the more challenging groups in oncology. MSS colorectal cancers have historically shown limited responsiveness to immunotherapy alone, making the search for combination approaches especially important. By pairing a peptide vaccine designed to stimulate a targeted immune response with an immune checkpoint inhibitor, researchers hope to give the body’s own defenses a better chance at recognizing and attacking cancer cells that have proven resistant to standard therapies.

The trial’s design reflects a thorough, methodical approach to patient safety and scientific rigor. Researchers will be closely monitoring not only the safety and tolerability of the combination treatment but also its immunogenicity — meaning how effectively the vaccine provokes a meaningful immune response — as well as early signs of clinical activity against the tumors. This structured evaluation is a foundational step that, if successful, could pave the way for larger trials and eventually broader treatment options for colorectal cancer patients who currently have few remaining choices.

What makes this development particularly encouraging is the innovative use of peptide vaccine technology in a cancer type that has been difficult to treat with immunotherapy alone. Peptide vaccines like PolyPEPI1018 are designed to train the immune system to recognize specific markers on cancer cells, potentially offering a more targeted and personalized approach to treatment. Combining this strategy with an already-approved immunotherapy agent represents the kind of thoughtful, incremental scientific progress that often leads to meaningful advances in patient care.

While it will take time to gather and analyze results from this trial, its very existence signals continued momentum in the peptide research field and a genuine effort to expand treatment possibilities for patients facing limited options. Trials like this one are essential building blocks toward future therapies, and the colorectal cancer community will be watching closely for updates as the study progresses.

This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on treatment options.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

A new Phase 2 clinical trial has been initiated to study VS-7375, an investigational therapy designed to target KRAS G12D-mutated metastatic colorectal cancer. This mutation represents a significant subset of colorectal cancer cases, and the KRAS gene has historically been considered one of the more challenging oncology targets to address with precision therapies. The launch of this trial reflects continued progress in the field of targeted cancer treatment.

According to the study listing on ClinicalTrials.gov, researchers will evaluate the safety and efficacy of VS-7375 both as a standalone treatment and in combination with other established therapies, including cetuximab, panitumumab, and the chemotherapy regimen mFOLFOX. This combination-focused approach is notable because it allows investigators to explore how VS-7375 might work alongside existing standard-of-care options, potentially expanding treatment strategies for patients who currently have limited targeted options for this particular mutation.

Phase 2 trials mark an important step in the drug development process, typically following earlier studies that establish preliminary safety and dosing information. Advancing to this stage suggests that VS-7375 has shown enough early promise to warrant further investigation in a broader patient population. For individuals and families affected by KRAS G12D-mutated colorectal cancer, the initiation of this trial offers a meaningful reason for cautious optimism, as it represents an additional avenue of research aimed at improving outcomes for a hard-to-treat cancer subtype.

The peptide and targeted therapy research space continues to evolve rapidly, with KRAS-directed treatments representing one of the more closely watched areas of oncology innovation in recent years. Trials like this one contribute valuable data that can help shape future treatment guidelines and expand the toolkit available to oncologists treating metastatic colorectal cancer. As enrollment and data collection proceed, the results will be closely watched by both the medical community and patient advocacy groups.

True North Labs will continue to monitor developments related to this and other promising peptide and targeted therapy research as new information becomes available. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer